G K Wenning Selected Research

Striatonigral Degeneration

8/2005	Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy).
4/2004	Effects of pulsatile L-DOPA treatment in the double lesion rat model of striatonigral degeneration (multiple system atrophy).
12/2002	Dystonia is predictive of subsequent altered dopaminergic responsiveness in a chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine+3-nitropropionic acid model of striatonigral degeneration in monkeys.
3/2002	A novel grading scale for striatonigral degeneration (multiple system atrophy).
1/2001	No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy).
1/2001	Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration.
7/2000	Failure of neuroprotection by embryonic striatal grafts in a double lesion rat model of striatonigral degeneration (multiple system atrophy).
5/2000	Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration.
3/2000	Towards neurotransplantation in multiple system atrophy: clinical rationale, pathophysiological basis, and preliminary experimental evidence.
1/2000	Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy).

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

G K Wenning Research Topics

Disease

17	Parkinsonian Disorders (Parkinsonism) 01/2013 - 01/2000
14	Multiple System Atrophy 02/2016 - 01/2000
11	Striatonigral Degeneration 08/2005 - 01/2000
8	Parkinson Disease (Parkinson's Disease) 01/2007 - 09/2000
6	Dementia (Dementias) 01/2007 - 04/2000
4	Dystonia (Limb Dystonia) 05/2004 - 03/2002
4	Dyskinesias (Dyskinesia) 04/2004 - 09/2000
4	Neurodegenerative Diseases (Neurodegenerative Disease) 04/2002 - 01/2000
3	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2020 - 08/2005
3	Disease Progression 10/2010 - 01/2001
3	Cerebellar Ataxia (Dysmetria) 08/2008 - 06/2001
3	Gliosis 03/2002 - 07/2000
2	Huntington Disease (Huntington's Disease) 02/2015 - 10/2001
2	Orthostatic Hypotension (Postural Hypotension) 01/2007 - 12/2005
2	Astrocytoma (Pilocytic Astrocytoma) 04/2002 - 09/2001
2	Atrophy 01/2001 - 05/2000
1	Tremor (Tremors) 01/2013
1	Frontotemporal Lobar Degeneration (Degeneration, Frontotemporal Lobar) 06/2011
1	Synucleinopathies 06/2011
1	Sarcoma (Soft Tissue Sarcoma) 06/2011
1	Pain (Aches) 05/2004
1	Torticollis (Wryneck) 07/2002
1	Benign essential blepharospasm 07/2002
1	Dystonic Disorders (Writer's Cramp) 03/2002
1	Cognitive Dysfunction 10/2001
1	Motor Disorders 06/2001
1	Syncope (Fainting) 12/2000
1	Neurogenic Urinary Bladder (Bladder, Neurogenic) 12/2000
1	Hallucinations (Hallucination) 12/2000
1	REM Sleep Behavior Disorder 12/2000
1	Traumatic Brain Injuries (Traumatic Brain Injury) 09/2000
1	Confusion (Bewilderment) 04/2000

Drug/Important Bio-Agent (IBA)

15	Levodopa (L Dopa)FDA LinkGeneric 10/2010 - 01/2000
4	Riluzole FDA LinkGeneric 10/2006 - 01/2001
4	alpha-SynucleinIBA 04/2002 - 01/2000
3	3-nitropropionic acidIBA 12/2002 - 05/2000
3	Quinolinic AcidIBA 01/2001 - 01/2000
2	Antipsychotic Agents (Antipsychotics)IBA 01/2013 - 12/2000
2	hydroxide ionIBA 01/2007 - 12/2005
2	Neuroprotective AgentsIBA 08/2005 - 01/2004
2	Botulinum Toxins (Botulinum Toxin)IBA 05/2004 - 03/2002
2	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 12/2002 - 05/2000
2	Type A Botulinum Toxins (Botox)FDA Link 07/2002 - 03/2002
2	Dopamine (Intropin)FDA LinkGeneric 01/2001 - 01/2000
2	Oxidopamine (6 Hydroxydopamine)IBA 01/2001 - 01/2000
2	Pharmaceutical PreparationsIBA 01/2001 - 09/2000
2	Apomorphine FDA Link 09/2000 - 01/2000
1	Carrier Proteins (Binding Protein)IBA 01/2020
1	DNA-Binding Proteins (DNA Binding Protein)IBA 06/2011
1	Biomarkers (Surrogate Marker)IBA 12/2005
1	DNA (Deoxyribonucleic Acid)IBA 12/2005
1	Protons (Proton)IBA 12/2005
1	AcidsIBA 12/2002
1	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 10/2001
1	Protein AggregatesIBA 09/2001
1	Red Fluorescent ProteinIBA 09/2001
1	SynucleinsIBA 09/2001
1	Glutamic Acid (Glutamate)FDA Link 01/2001
1	Acetylcholine (Acetylcholine Chloride)FDA Link 12/2000
1	Cholinergic Antagonists (Anticholinergics)IBA 12/2000
1	EsterasesIBA 12/2000
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 09/2000
1	3- iodo- 2- hydroxy- 6- methoxy- N- ((1- ethyl- 2- pyrrolidinyl)methyl)benzamideIBA 09/2000
1	Amantadine (Aman)FDA LinkGeneric 09/2000
1	PK 11195 (PK11195)IBA 07/2000
1	BenzodiazepinesIBA 07/2000
1	SCH 23390IBA 01/2000
1	spiroperidol receptorIBA 01/2000
1	Mazindol (Mazanor)FDA Link 01/2000
1	Amphetamine (Amfetamine)FDA LinkGeneric 01/2000

Therapy/Procedure

9	Therapeutics 02/2016 - 09/2000
3	Transplantation 01/2001 - 01/2000
1	Activities of Daily Living (ADL) 05/2004
1	Denervation 12/2002
1	Injections 03/2002
1	Drug Therapy (Chemotherapy) 03/2002
1	Aftercare (After-Treatment) 09/2000